Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Oncology
  • Oncology News
  • Is Etirinotecan Pegol...

Is Etirinotecan Pegol better than chemotherapy in treating Brain Metastases?

Medical Dialogues Editorial TeamWritten by Medical Dialogues Editorial Team Published On 2022-05-15T21:30:46+05:30  |  Updated On 15 May 2022 4:04 PM GMT
Is Etirinotecan Pegol better than chemotherapy in treating Brain Metastases?
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • koo
  • Email

The findings of the ATTAIN randomized clinical study, published in the Journal of the American Medical Association, showed no statistical difference in outcomes between etirinotecan pegol treatment and chemotherapy in patients with brain metastases (BM).Patients with breast cancer with brain metastases have such a poor prognosis and a significant clinical need for innovative...

The findings of the ATTAIN randomized clinical study, published in the Journal of the American Medical Association, showed no statistical difference in outcomes between etirinotecan pegol treatment and chemotherapy in patients with brain metastases (BM).

Patients with breast cancer with brain metastases have such a poor prognosis and a significant clinical need for innovative therapies; nonetheless, these patients have typically been excluded from research. Although the BEACON study's primary endpoint was not met, treatment with etirinotecan pegol vs chemotherapy of the physician's choice for patients with advanced breast cancer showed significant improvements in overall survival (OS) for the predefined patient subgroup with preexisting, pretreated, and nonprogressive BM. In a confirmatory trial, Debu Tripathy and colleagues compared clinical outcomes in patients with BM treated with etirinotecan pegol with chemotherapy of the physician's choice.

This was a phase 3 open-label, randomized clinical trial (ATTAIN) in patients with metastatic breast cancer with a history of stable pretreatment BM who encountered disease progression while undergoing metastatic chemotherapy. Patients were enrolled in the experiment at 47 locations across ten countries between March 7, 2017, and November 6, 2019. Patients were randomly assigned to either 145 mg/m2 etirinotecan pegol or chemotherapy every 21 days (eribulin, ixabepilone, vinorelbine, paclitaxel, gemcitabine, docetaxel, or nab-paclitaxel). OS was the major goal. The progression-free survival, objective response rate, durability of response, and clinical benefit rate were all important secondary end goals.

The key findings of this study were as follow:

1. A maximum of 178 female patients were randomly assigned to undergo etirinotecan pegol therapy.

2. In both groups, the median OS was comparable.

3. According to a blinded independent central review, the median progression-free survival for non–central nervous system metastases with etirinotecan pegol versus chemotherapy was 2.8 and 1.9 months, respectively.

4. The groups' safety profiles were basically comparable.

In conclusion, the findings of this and other research illustrate the viability of trials in this population of breast cancer and BM patients, as well as the relevance of verifying findings from subgroup analysis.

Reference:

Tripathy, D., Tolaney, S. M., Seidman, A. D., Anders, C. K., Ibrahim, N., Rugo, H. S., Twelves, C., Diéras, V., Müller, V., Du, Y., Currie, S. L., Hoch, U., Underhill, C. R. (2022). Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases. In JAMA Oncology. American Medical Association (AMA). https://doi.org/10.1001/jamaoncol.2022.0514


Etirinotecan Pegolbrain metastasesjama oncology
Source : JAMA Oncology
Medical Dialogues Editorial Team
Medical Dialogues Editorial Team

    Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X